NCT02905019View on ClinicalTrials.gov

A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

December 21, 2017

Study Completion Date

December 21, 2017

Conditions
Malaria
Interventions
BIOLOGICAL

R21 with Matrix-M1

Vaccine

BIOLOGICAL

ChAd63 ME-TRAP

Vaccine

BIOLOGICAL

MVA ME-TRAP

Vaccine

Trial Locations (3)

Unknown

NIHR Wellcome Trust Clinical Research Facility, Hammersmith Hospital, London

Southampton National Institute for Health Research, Southampton

OX3 7LE

CCVTM, University of Oxford,, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT02905019 - A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP | Biotech Hunter | Biotech Hunter